Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

1. Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.Blood advances · 2026
   Trial
2. A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.Leukemia · 2026
   Review
3. Pegylated interferon: the who, why, and how.Hematology. American Society of Hematology. Education Program · 2024
   Review
4. Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.Cancers · 2020
   Review
5. Guidelines for the management of myeloproliferative neoplasms.The Korean journal of internal medicine · 2015
   Review
6. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Bone marrow transplantation · 2015
   Review
7. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.Mediators of inflammation · 2015
   Review
8. How to manage children and young adults with myeloproliferative neoplasms.Leukemia · 2012
   Article
9. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.Current medicinal chemistry · 2012
   Review

Corrections and comments

• Comment on
  Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.2011
• Comment on
  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.2011

Authors and funding

3 authors at 3 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as